Elacridar
Elacridar is an orally active P-glycoprotein (Pgp) and breast cancer resistance protein (BCRP) inhibitor. Elacridar can be used to examine the influence of efflux transporters on agent distribution to brain and the research of cancer[1][2].
Product Specifications
CAS Number
[143664-11-3]
Product Name Alternative
GF120918; GW0918; GG918; GW120918
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
BCRP; P-glycoprotein
Type
Reference compound
Related Pathways
Membrane Transporter/Ion Channel
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/elacridar.html
Purity
99.66
Solubility
DMSO : 5 mg/mL (ultrasonic)
Smiles
O=C1C2=CC=CC(C(NC(C=C3)=CC=C3CCN4CC(C=C(C(OC)=C5)OC)=C5CC4)=O)=C2NC6=C1C=CC=C6OC
Molecular Formula
C34H33N3O5
Molecular Weight
563.64
Precautions
H302, H315, H319, H335
References & Citations
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Phase 1
Citation 01
Available Sizes
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items